Black Diamond Therapeutics, Inc. SEC filings BDTX
Black Diamond Therapeutics, Inc. has 485 filings in SEC EDGAR's recent list, going back to Mar 28, 2017. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 16, 2026 | Mar 16, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Dec 3, 2025 | Dec 3, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 19, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2025 | Mar 6, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2024 | Nov 5, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Oct 7, 2024 | Oct 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 23, 2024 | Sep 23, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 6, 2024 | Jun 6, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 11, 2024 | Apr 10, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2024 | Mar 12, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 18, 2024 | Jan 17, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 4, 2024 | Jan 4, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 13, 2023 | Dec 13, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2023 | Nov 6, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 18, 2023 | Sep 15, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2023 | Aug 11, 2023 |
| 8-K |
Current report
Material agreement
|
Jun 30, 2023 | Jun 29, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 27, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Shareholder vote results
|
May 16, 2023 | May 16, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2023 | Mar 9, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 19, 2022 | Dec 13, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 12, 2022 | Dec 12, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2022 | Nov 8, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2022 | Jun 7, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 25, 2022 | Apr 25, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 7, 2022 | Apr 5, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2022 | Mar 17, 2022 |
| 8-K |
Current report
Other events
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Officer or director change
|
Nov 22, 2021 | Nov 16, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2021 | Nov 8, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2021 | Aug 9, 2021 |
| 8-K |
Current report
Officer or director change
|
Aug 5, 2021 | Aug 4, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2021 | Jun 18, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 19, 2021 | May 19, 2021 |
| 8-K |
Current report
Results of operations
|
May 7, 2021 | May 7, 2021 |
| 8-K | Current report | Apr 21, 2021 | Apr 21, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 25, 2021 | Mar 25, 2021 |
| 8-K |
Current report
Other events
|
Mar 15, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Material agreement
|
Feb 1, 2021 | Feb 1, 2021 |
| 8-K |
Current report
Officer or director change
|
Jan 20, 2021 | Jan 19, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2020 | Nov 10, 2020 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2020 | Sep 25, 2020 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2020 | Aug 11, 2020 |
| 8-K |
Current report
Results of operations
|
May 12, 2020 | May 12, 2020 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2020 | Mar 24, 2020 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 3, 2020 | Feb 3, 2020 |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BDTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1701541
- Former names
- Aset Therapeutics, Inc. (until Jan 4, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.